27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Shares of Bristol-Myers Squibb Company (NYSE:BMY) and 2seventy Bio Inc (NASDAQ:TSVT) fell after the companies' efforts to win expanded U.S. approval for its Abecma gene therapy hit a delay.
The FDA's Oncologic Drugs Advisory Committee (ODAC) will meet to review data supporting the supplemental Biologics License Application (sBLA) for Abecma (idecabtagene vicleucel) for earlier lines of triple-class exposed relapsed or refractory multiple myeloma (RRMM) based on results from the pivotal Phase 3 KarMMa-3 study.
Also Read: 2seventy Bio's Cost Cuts Prudent, But Analyst Says It Induces Lower Confidence In Lead Product.
The FDA has not yet confirmed the date of the ODAC meeting. The FDA also informed the companies that a decision on the application will not be made by the Prescription Drug User Fee Act (PDUFA) target action date of December 16, 2023.
Abecma is currently approved for adults with triple-class exposed RRMM after four or more prior lines of therapy.
Abecma generated $69 million U.S. commercial revenue in Q3 FY23 and $302 million U.S. commercial revenue year-to-date.
The KarMMa-3 study met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival compared to standard regimens, significantly reducing the risk of disease progression or death versus standard regimens.
Price Action: TSVT stock is down 20.65% at $1.65, and BMY shares are down 2.75% at $49.44 on the last check Monday.
Photo Via Company
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!